Table 2.

The sensitivity and specificity of each commercial immunoassay.

Assays	Sensitivity (95% CI)				Specificity (95% CI)
	1st week (6.1 d) N = 34	2nd week (11.2 d) N = 35	3rd week (17.8 d) N = 38	Overall N = 107	<2016 sera N = 52	Non-COVID-19 sera N = 58	Overall N = 110
Abbott IgG	19 55.9% (46.5–65.3)	30 85.7% (79.1–92.3)	38 100% (99.3–100)	87 81.3% (73.9–88.7)	52 100% (99,3–100)	57 98.3% (95.9–100)	109 99.1% (97.3–100)
FRENDTM IgG	21 61.8% (52.6–71.0)	33 94.3% (89.9–98.7)	38 100% (99.3–100)	92 85.9% (79.3–92.5)	51 98.1% (95.5–100)	57 98.3% (95.9–100)	108 98.2% (95.7–100)
Roche total antibodies	17 50% (41.1–58.9)	33 94.3% (90.2–98.5)	37 97.4% (94.6–100)	87 81.3% (73.9–88.7)	51 98.1% (95.7–100)	57 98.3% (95.9–100)	108 98.2% (95.7–100)
Snibe IgG	17 50% (40.5–59.5)	31 88.6% (82.6–94.6)	37 97.4% (94.4–100)	85 79.4% (71.7–87.1)	48 92.3% (87.3–97.3)	57 98.3% (95.9–100)	105 95.5% (91.6–99.4)
Beckman IgG	18 52.9% (43.4–62.4)	32 91.4% (86.1–96.7)	37 97.4% (94.4–100)	87 81.3% (73.9–88.7)	52 100% (99.3–100)	58 100% (99.3–100)	110 100% (99.3–100)
Mindray IgG	20 58.8% (49.5–68.1)	32 91.4% (86.1–96.7)	38 100% (99.3–100)	90 84.1% (77.2–91.0)	52 100% (99.3–100)	58 100% (99.3–100)	110 100% (99.3–100)
Mindray total antibodies	24 70.6% (61.9–79.2)	32 91.4% (86.1–96.7)	38 100% (99.3–100)	94 87.9% (81.7–94.1)	52 100% (99.3–100)	56 96.6% (93.2–99.9)	108 98.2% (95.7–100)
Siemens total antibodies	16 47.1% (37.6–56.6)	30 85.7% (79.1–92.3)	37 97.4% (94.4–100)	83 77.6% (69.7–85.5)	51 98.1% (95.5–100)	58 100% (99.3–100)	109 99.1% (97.3–100)
Vazyme sVNT	25 73.5% (65.1–81.9)	34 97.1% (93.9–100)	38 100% (99.3–100)	97 90.7% (85.2–96.2)	51 98.1% (95.5–100)	56 96.6% (93.2–99.9)	107 97.3% (94.3–100)
GenScript sVNT	20 58.8% (49.5–68.1)	33 94.3% (90.2–98.5)	38 100% (99.3–100)	91 85.0% (78.2–91.8)	51 98.1% (95.5–100)	58 100% (99.3–100)	109 99.1% (97.3–100)